Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Difficile Infections (Clostridium Difficile Associated Disease) Treatment Market Snapshot (2023 to 2033)

The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market size is expected to surpass an impressive valuation of US$ 809 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033 to be valued at US$ 1,448.75 Million.

Clostridium difficile infection (CDI) is an illness caused by toxic substances generated by the "Clostridium difficile" spore-forming bacteria living in the big intestine. It belongs to the closely connected causal factors of antibiotic-related diarrhea, with signs ranging from mild, self-limiting diarrhea to chronic diarrhea, pseudomembranous colitis, and potentially fatal fulminant colitis. Antimicrobial drug consumption is predicted to drive expansion in the Clostridium difficile infection therapeutics market.

Report Attribute Details
Expected Market Value (2022) US$ 801 Million
Market Value (2023) US$ 809 Million
Anticipated Forecast Value (2033) US$ 1,448.75 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Difficile Infections (Clostridium Difficile Associated Disease) Treatment Demand Analysis vs. Forecast 2023 to 2033

Over the historical era, the difficile infection treatment market was influenced by the increasing incidence of clostridium-related illness and the growing worldwide aging population. Growing urbanization, an advanced healthcare system, and innovative technologies also enhanced market growth in the past years.

The aging global population is projected to propel the Clostridium Clostridium Difficile Infection Treatment market throughout the forecast period. Furthermore, modern lifestyles, advanced healthcare systems, and technological developments are predicted to propel market growth over the next several years. Also, the widespread use is expected to accelerate the expansion of the worldwide clostridium difficile infection treatment market.

Furthermore, the COVID-19 pandemic had a brief influence on the Clostridium Difficile Infection Therapeutics Market, as sales dropped during the virus's outbreak in 2020 due to massive losses in lifestyles and the global economy. Nevertheless, the industry regained following the development of vaccines and the withdrawal of COVID-19 restrictions.

Which are Some Prominent Drivers of the Difficile Infections (Clostridium Difficile Associated Disease) Treatment Market?

Rising Utilization of Antibiotics to Accelerate Market Growth

Excessive drug development projects for creating and marketing new drugs are estimated to drive growth in the clostridium difficile infection treatment market by offering therapists a new therapeutic option. Moreover, the introduction of a new class of non-antibiotic medications and vaccines is expected to provide a plethora of possibilities for market participants while also growing the competitiveness for developing novel drugs as superior therapeutic approaches. As a result, higher drug programs for novel drugs to improve treatment and prevention are expected to propel the market's growth in the coming years.

Rising Utilization of Antibiotics accelerates Market Growth

Long-term antibiotic consumption is the most common cause of Clostridium difficile infection. Antibacterial drugs use changes the colorectal bacteria, enabling Clostridium difficile bacteria to thrive. Cephalosporins, clindamycin, and quinolone antibiotics seem to be more susceptible to causing Clostridium difficile infection (CDI).

The elevated utilization of these antibiotics is expanding the likelihood of Clostridium difficile infection, which is predicted to boost the requirement for its treatments. As a result, increased antibiotic usage is an important driver of expansion in the worldwide clostridium difficile infection treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Substantial Investments Required for Drug Development to restrict the market growth

Antibiotics are the only ongoing effective treatments for CDIs, and several pharmaceutical companies are attempting to develop non-antibiotic alternative solutions. The creation of a brand-new class of drugs will provide ample opportunities for industry participants to thrive, but it will also necessitate huge investments in novel therapy advancement and research. The significantly greater capital investments may act as a major impediment to industry growth.

Region-Wise Insights

What Makes Europe the Largest Market for difficile Infections (Clostridium Difficile Associated Disease) Treatment?

Increased awareness of gastrointestinal infections drives the market growth

Because the infection is getting less prevalent, the market for clostridium difficile infection treatments is decreasing in European countries. The number of fatalities caused by healthcare-related CDI in Europe can be approximated at 3700 per year.

Because of the existence of mandatory monitoring, there has been improved compliance with isolation, personal hygiene, and cleanliness protocols, in addition to the tracking of antibiotic prescriptions. Because of greater awareness about gastrointestinal infection in the region, Europe is regarded as the second largest industry for clostridium difficile infection drugs.

Why is North America Considered a Lucrative Region for the Difficile Infections (Clostridium Difficile Associated Disease) Treatment Market?

An increase in suspected cases of difficile Infections (Clostridium Difficile Associated Disease) Treatment spurs the market

According to the Centers for Disease Control (CDC), clostridium difficile infects about half a million North Americans every year. Within one month of being diagnosed with C. difficile, nearly 29,000 patients died, with 15,000 of these death tolls being mainly ascribed to C. difficile infection. The Clostridium Difficile Infection industry will emerge significantly in the next few years as healthcare expenditure in this region rises, suspected cases of Clostridium difficile infection (CDI) increase and forthcoming treatments are anticipated to be launched.

With developments in molecular biology methods over the last two decades, there have been numerous advancements in comprehending the genetic variety, evolution, and pathogenicity of Clostridium difficile. In North America, recurring clinical and academic activities are anticipated to continue to resolve impediments in the coming decades. Furthermore, the United States had the highest proportion of Clostridium difficile infection, accounting for nearly 70% of all cases reported of Clostridium difficile infection worldwide.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Therapy Segment Will Grow Rapidly?

The antibiotic segment is projected to expand quickly

Recently, standard antibiotics such as metronidazole, Vancomycin, and Fidaxomicin have been employed to cure Clostridium difficile infection (CDI). Presently, there are no alternatives to antibiotics for the treatment of Clostridium difficile infection, and surgical procedure remains the only option (in severe cases). As a result, the antibiotic segment is expected to grow rapidly over the forecast timeframe.

Which End User Segment will emerge as Market Leader?

A rise in the number of hospitalized patients drives the market growth

The end-user market is dominated by the hospital segment. This, coupled with an increase in hospitalized patients and a greater focus on public health agencies, is anticipated to propel Hospital segment expansion during the forecast period.

Start-ups offering Treatment for Difficile Infections

  • Acurx Pharmaceuticals is a publicly traded biopharmaceutical company in the clinical stages of developing a novel category of antibiotics for infections. Acurx Pharmaceuticals, based in the United States and founded in 2017, offers Ibezapolstat antibiotics for the diagnosis of difficile Infections (Clostridium Difficile Associated Disease) Treatment.
  • As Seres Therapeutics, a microbiome startup founded in 2010, prepares to submit its C. difficile treatment to the US Food and Drug Administration, it has enlarged its collaboration with Nestlé Health, which is offering up to $500 million to monetize the drug.

Market Competition

Key players in the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market are Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.

  • Thermo Fisher ScientificTM XpectTM C. difficile Toxin A/B Test, which was launched in September 2021 by Thermo Fisher Scientific Inc, detects Clostridium difficile toxins A and B in human fecal specimens. It incorporates superior clinical efficiency with a simple three-step method.
  • Tech Lab's TOX A/B QUIK CHEK® test is a rapid enzymatic immunoassay that was launched in February 2021. The test employs antibodies against C. difficile toxins A and B. The device comprises a Response Window with two stripes. One stripe denotes a toxin A and B test line. The other striped line is the monitoring line.

Report Scope

Report Attribute Details
Market Value (2023) US$ 809 Million
Anticipated Forecast Value (2033) US$ 1,448.75 Million
Projected Growth Rate (2023 to 2033) 6% CAGR
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • Drug Type
  • End Users
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • The US
  • Canada
  • Brazil
  • Mexico
  • Mexico
  • BENELUX
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Nordics
  • Poland
  • Russia
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Merck & Co. Inc.
  • Baxter International Inc.
  • Sanofi S.A
  • Pfizer Inc.
  • Novartis AG
  • Astellas Pharma
  • Eli Lily & Company
  • AstraZeneca
  • Actelion Pharmaceuticals Ltd.
  • Mylan N.V
Customization Available Upon Request

Key Segments Profiled in the Difficile Infections (Clostridium Difficile Associated Disease) Treatment Market Industry Survey 

By Treatment:

  • Antimicrobial Therapy
  • Faecal Microbiota Transplantation

By Drug Type:

  • Metronidazole
  • Vancomyci
  • Fidaxomicin

By End User:

  • Hospital
  • Pharmacies
  • ASCs

By Region:

  • North America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

What is the anticipated growth of the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market until 2033?

FMI projects the global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market to expand at a 6% value CAGR by 2033.

What is the estimated market value of the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market expected in 2023?

The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is estimated at a market value of US$ 809 Million.

What is the estimated market value of the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market expected in 2033?

The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is expected to garner a market value of US$ 1,448.75 Million.

Which region is forecast to be the most lucrative for Difficile Infections (Clostridium Difficile Associated Disease) Treatment market growth?

FMI has projected North America to be one of the key regions for the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market.

Which are some prominent Difficile Infections (Clostridium Difficile Associated Disease) Treatment manufacturers?

Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, AstraZeneca Plc.

Table of Content

1. Executive Summary | Difficile Infections (Clostridium Difficile Associated Disease) Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Antimicrobial Therapy

        5.3.2. Faecal Microbiota Transplantation

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        6.3.1. Metronidazole

        6.3.2. Vancomycin

        6.3.3. Fidaxomicin

    6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        7.3.1. Hospital

        7.3.2. Pharmacies

        7.3.3. ASCs

    7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. Asia-Pacific

        8.3.6. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The US

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Drug Type

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Drug Type

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Drug Type

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Drug Type

        10.3.4. By End Users

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Benelux

            11.2.1.2. France

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. Nordic

            11.2.1.6. Spain

            11.2.1.7. The UK

            11.2.1.8. Rest of Western Europe

        11.2.2. By Treatment

        11.2.3. By Drug Type

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Drug Type

        11.3.4. By End Users

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Rest of Eastern Europe

        12.2.2. By Treatment

        12.2.3. By Drug Type

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Drug Type

        12.3.4. By End Users

    12.4. Key Takeaways

13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Australia

            13.2.1.6. New Zealand

            13.2.1.7. Rest of APAC

        13.2.2. By Treatment

        13.2.3. By Drug Type

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Drug Type

        13.3.4. By End Users

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Treatment

        14.2.3. By Drug Type

        14.2.4. By End Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Drug Type

        14.3.4. By End Users

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. The US

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Treatment

            15.1.2.2. By Drug Type

            15.1.2.3. By End Users

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Treatment

            15.2.2.2. By Drug Type

            15.2.2.3. By End Users

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Treatment

            15.3.2.2. By Drug Type

            15.3.2.3. By End Users

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Treatment

            15.4.2.2. By Drug Type

            15.4.2.3. By End Users

    15.5. Benelux

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Treatment

            15.5.2.2. By Drug Type

            15.5.2.3. By End Users

    15.6. France

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Treatment

            15.6.2.2. By Drug Type

            15.6.2.3. By End Users

    15.7. Germany

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Treatment

            15.7.2.2. By Drug Type

            15.7.2.3. By End Users

    15.8. Italy

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Treatment

            15.8.2.2. By Drug Type

            15.8.2.3. By End Users

    15.9. Nordic

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Treatment

            15.9.2.2. By Drug Type

            15.9.2.3. By End Users

    15.10. Spain

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Treatment

            15.10.2.2. By Drug Type

            15.10.2.3. By End Users

    15.11. The UK

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Treatment

            15.11.2.2. By Drug Type

            15.11.2.3. By End Users

    15.12. Poland

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Treatment

            15.12.2.2. By Drug Type

            15.12.2.3. By End Users

    15.13. Russia

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Treatment

            15.13.2.2. By Drug Type

            15.13.2.3. By End Users

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Treatment

            15.14.2.2. By Drug Type

            15.14.2.3. By End Users

    15.15. Malaysia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Treatment

            15.15.2.2. By Drug Type

            15.15.2.3. By End Users

    15.16. Singapore

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Treatment

            15.16.2.2. By Drug Type

            15.16.2.3. By End Users

    15.17. Thailand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Treatment

            15.17.2.2. By Drug Type

            15.17.2.3. By End Users

    15.18. Australia

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Treatment

            15.18.2.2. By Drug Type

            15.18.2.3. By End Users

    15.19. New Zealand

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Treatment

            15.19.2.2. By Drug Type

            15.19.2.3. By End Users

    15.20. GCC Countries

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Treatment

            15.20.2.2. By Drug Type

            15.20.2.3. By End Users

    15.21. South Africa

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Treatment

            15.21.2.2. By Drug Type

            15.21.2.3. By End Users

    15.22. Israel

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Treatment

            15.22.2.2. By Drug Type

            15.22.2.3. By End Users

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Treatment

        16.3.3. By Drug Type

        16.3.4. By End Users

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Merck & Co., Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Baxter International Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Sanofi S.A.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Pfizer Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Novartis AG

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Astellas Pharma

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Eli Lily & Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. AstraZeneca

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Actelion Pharmaceuticals Ltd

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Mylan N.V.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: APAC Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 23: APAC Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 24: APAC Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 27: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 28: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 18: Global Market Attractiveness by Drug Type, 2023 to 2033

Figure 19: Global Market Attractiveness by End Users, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 38: North America Market Attractiveness by Drug Type, 2023 to 2033

Figure 39: North America Market Attractiveness by End Users, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Drug Type, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by End Users, 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by End Users, 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: APAC Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 102: APAC Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 103: APAC Market Value (US$ Million) by End Users, 2023 to 2033

Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: APAC Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 109: APAC Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 110: APAC Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 111: APAC Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 112: APAC Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 113: APAC Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 114: APAC Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 115: APAC Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 116: APAC Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 117: APAC Market Attractiveness by Treatment, 2023 to 2033

Figure 118: APAC Market Attractiveness by Drug Type, 2023 to 2033

Figure 119: APAC Market Attractiveness by End Users, 2023 to 2033

Figure 120: APAC Market Attractiveness by Country, 2023 to 2033

Figure 121: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 122: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 123: MEA Market Value (US$ Million) by End Users, 2023 to 2033

Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 129: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 130: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 131: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 132: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 134: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 135: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 136: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 137: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 138: MEA Market Attractiveness by Drug Type, 2023 to 2033

Figure 139: MEA Market Attractiveness by End Users, 2023 to 2033

Figure 140: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Clostridium Diagnostics Market

Published : July 2022

Healthcare

Faecal Extraction System Market

Published : October 2021

Explore Healthcare Insights

View Reports

Difficile Infections (Clostridium Difficile Associated Disease) Market